Since CYP4F12 has been shown to inhibit tumor cell migration in vitro, we hypothesized that CYP4F12 may be a promising HNSC biomarker that could predict anticancer therapy efficacy and patient prognosis. Here, CYP4F12 is linked to neoplasm.